Medicus Pharma Ltd

Contributing Author

Recent Articles by Medicus Pharma Ltd

Jul-16	Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix Novel Study in Acute Urinary Retention MDCX +16.53% GlobeNewswire
Jun-22	Medicus Pharma to Showcase SkinJect Registrational Strategy and Teverelix Precision Medicine Program at Bio International 2026 MDCX GlobeNewswire
Jun-15	Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect in Gorlin Syndrome MDCX -5.24% GlobeNewswire
Jun-11	Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix in Endometriosis utilizing the Emirati Genome Program MDCX GlobeNewswire
Jun-08	Medicus Pharma Advances Teverelix Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission MDCX GlobeNewswire
Jun-03	Medicus Pharma Advances SkinJect into Registrational Development for Gorlin Syndrome MDCX +6.97% GlobeNewswire
May-28	Medicus Pharma Announces $22 Million Non-Dilutive Financing MDCX +6.74% GlobeNewswire
May-14	Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update MDCX +5.28% MDCX -10.68% GlobeNewswire
May-06	Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response MDCX +20.95% GlobeNewswire
Apr-27	Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill MDCX -5.68% GlobeNewswire
Apr-17	Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect in Gorlin Syndrome MDCX +16.98% GlobeNewswire
Apr-15	Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression MDCX -25.04% GlobeNewswire
Apr-06	Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention MDCX +9.82% GlobeNewswire
Apr-01	Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset MDCX -8.50% GlobeNewswire
Mar-30	Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate MDCX -9.64% GlobeNewswire
Mar-26	Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan MDCX -5.71% GlobeNewswire
Mar-16	Medicus Pharma Announces SkinJect Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26 MDCX GlobeNewswire
Mar-09	Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect Dataset MDCX +34.26% GlobeNewswire
Mar-05	Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort MDCX -50.88% GlobeNewswire
Mar-03	Medicus Pharma To Participate in the 38th Annual Roth Conference MDCX GlobeNewswire
Feb-10	Medicus Pharma Receives FDA "Study May Proceed" Clearance For Teverelix Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk MDCX GlobeNewswire
Jan-22	Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix Long-Term Economic and Development Profile MDCX GlobeNewswire
Jan-20	Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026 MDCX GlobeNewswire
Jan-12	Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women MDCX -5.81% GlobeNewswire
Jan-05	Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates MDCX GlobeNewswire
Dec-15	Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin MDCX GlobeNewswire
Nov-24	Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers MDCX -7.04% GlobeNewswire

Medicus Pharma Ltd

Recent Articles by Medicus Pharma Ltd

Upgrade your Finviz experience